| [1] |
Slamon DJ, Leyland Jones B, Shak S, et al.Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2[J].N Engl J Med, 2001,344(11): 783-792.
|
| [2] |
Marty M, Cognetti F, Maraninchi D,et al.Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J].J Clin Oncol, 2005,23(19): 4265-4274.
|
| [3] |
王涛,江泽飞,宋三泰,等.单药赫赛汀® 治疗复发转移性乳腺癌[J].中华肿瘤杂志,2004,26(7):430-432.
|
| [4] |
Romond EH, Perez EA, Bryant J, et al.Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer[J].N Engl J Med, 2005, 353(16): 1673-1684.
|
| [5] |
Piccart Gebhart MJ, Procter M, Leyland Jones B, et al.Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer[J].N Engl J Med, 2005,353(16): 1659-1672.
|
| [6] |
Slamon DJ, Eiermann W, Robert N, et al.Phase Ⅲ randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel(ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab(ACTH) with docetaxel,carboplatin and trastuzumab(TCH) in HER-2 positive early breast cancer patients: BCIRG 006 study[J].Breast Cancer Res Treat, 2005,94(suppl):S5.
|
| [7] |
Gianni L, Dafni U, Gelber RD, et al.Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomized controlled trial[J].Lancet Oncology (Online),2011, 12(3): 236-244.
|
| [8] |
Perez EA, Suman VJ, Davidson NE, et al.Results of chemotherapy alone, with sequential or concurrent addition of trastuzumab in the NCCTG N9831 HER2-positive Adjuvant Breast Cancer Trial: the 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009 [C].San Antonio, Texas: CTRC-AACR,2009.
|
| [9] |
Dawood S, Broglio K, Buzdar AU, et al.Prognosis of women with metastatic breast cancer by HER-2 status and trastuzumab treatment: an institutional-based review[J].J Clin Oncol, 2010, 28(1): 92-98.
|
| [10] |
Minckwitz GV, Zielinski C, Maarteense E, et al.Capecitabine vs.capecitabine + trastuzumab in patients with HER-2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05)[J].J Clin Oncol, 2008, 26(158):1025.
|
| [11] |
Geyer CE, Schwartz G, Lindquist D, et al.Lapatinib plus capecitabine for HER-2-positive advanced breast cancer[J].N Engl J Med,2006,355(26):2733-2743.
|
| [12] |
O'Shaughnessy J, Blackwell KL, Bursein H, et al.A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER-2+ metastatic breast cancer progressing on trastuzumab therapy[J].Proc Am Soc Clin Oncol,2008,26(suppl 15):1015.
|
| [13] |
Lewis Phillips GD, Li G, Dugger DL, et al.Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate[J].Cancer Res, 2008,68:9280-9290.
|
| [14] |
Vogel CL, Burris HA, Limentani S, et al.A phase Ⅱ study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results[J].J Clin Oncol,2009,27(suppl):15s.
|
| [15] |
Agus DB, Akita RW, Fox WD, et al.Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth[J].Cancer Cell,2002,2(2):127-137.
|
| [16] |
Folkman J.Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J].Exp Cell Res,2005, 312(5): 594-607.
|
| [17] |
Miller KD, Wang M, Gralow J, et al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J].N Engl J Med,2007,357:2666-2676.
|
| [18] |
Miles D, Chan A, Romieu G, et al.Randomized, double-blind, placebo-controlled, phase Ⅲ study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer:AVADO[J].J Clin Oncol, 2008,26(suppl): 15s.
|
| [19] |
Robert NJ, Dieras V, Glaspy J, et al.RIBBON-1: randomized, double-blind, placebo-controlled, phase Ⅲ trial of chemotherapy with or without bevacizumab for first-line treatment of HER-2-negative locally recurrent or metastatic breast cancer[J].J Clin Oncol, 2009, 27(suppl): 15s.
|
| [20] |
Ranpura V, Hapani S, Wu S.Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis[J].JAMA, 2011, 305(5): 487-494.
|
| [21] |
Gradishar WJ, Kaklamani V, Prasad TS, et al.A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer[J].Cancer Res,2009,69(Suppl):44.
|
| [22] |
Baselga J,Roché H, Costa F, et al.SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafinib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC) [J].Cancer Res, 2009,69(Suppl): 45.
|
| [23] |
Barrios CH, Liu MC, Lee SC, et al.Phase Ⅲ randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer[J].Breast Cancer Res Treat, 2010,121(1): 121-131.
|
| [24] |
Baselga J, Semiglazov V, van Dam P, et al.Phase Ⅱ randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with eatrogen receptor-positive breast cancer[J].J Clin Oncol, 2009, 27(16): 2630-2637.
|
| [25] |
O'Shaughnessy J, Osborne C, Pippen J, et al.Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1)inhibitor, in combination with gemcitabine/carboplatin in patients with metastatic triple negative cancer: results of a randomized phase Ⅱ trial[J].J Clin Oncol,2009,27(suppl): 18s.
|
| [26] |
Tutt A, Robson M, Garber JE, et al.Phase Ⅱ trial of the oral PARP inhibitor Olaparib in BRCA-deficient advanced breast cancer[J].J Clin Oncol,2009, 27(suppl): 18s.
|